MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Chimerix Company Profile (NASDAQ:CMRX)

Consensus Ratings for Chimerix (NASDAQ:CMRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 10 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.08)
Consensus Price Target: $18.82 (404.51% upside)

Analysts' Ratings History for Chimerix (NASDAQ:CMRX)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016FBR & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016Citigroup Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016William BlairLower Price TargetMarket Perform$12.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016BarclaysDowngradeOverweight -> Equal Weight$12.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Morgan StanleyDowngradeEqual Weight -> Underweight$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/4/2016JPMorgan Chase & Co.DowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/3/2016Brean CapitalDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/3/2016Cowen and CompanyDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/3/2016Stifel NicolausDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015EmpireReiterated RatingEqual WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015Janney Montgomery ScottLower Price TargetNeutral$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2015Cantor FitzgeraldReiterated RatingBuy$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Chimerix (NASDAQ:CMRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q1($0.66)($0.57)$2.79 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.14)($0.82)$8.07 million$3.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.59)($0.70)$5.01 million$2.27 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.58)($0.59)$1.37 million$4.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.59)($0.54)$1.19 million$1.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2015Q414($0.51)($0.52)$1.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.41)($0.47)$1.19 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.44)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q1 14($0.36)($0.39)$0.85 million$0.78 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2014Q413($0.41)($0.31)$1.19 million$0.88 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.38)($0.26)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q2 2013($0.40)($0.91)$1.91 million$0.81 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q1 2013($2.43)($22.58)$1.00 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Chimerix (NASDAQ:CMRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.80)($0.45)($0.67)
Q2 20162($0.49)($0.48)($0.49)
Q3 20162($0.42)($0.40)($0.41)
Q4 20162($0.45)($0.38)($0.42)
(Data provided by Zacks Investment Research)
Dividend History for Chimerix (NASDAQ:CMRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Chimerix (NASDAQ:CMRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016Ernest MarioDirectorBuy10,000$4.53$45,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Ernest MarioDirectorBuy25,000$4.85$121,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2016Ernest MarioDirectorBuy800$4.76$3,808.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Ernest MarioDirectorBuy25,000$5.06$126,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Ernest MarioDirectorBuy20,000$5.13$102,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Martha J DemskiDirectorBuy10,000$4.89$48,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Ernest MarioDirectorBuy125,000$7.09$886,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Martha J. DemskiDirectorSell1,126$41.35$46,560.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Martha J. DemskiDirectorSell2,000$37.68$75,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Martha J. DemskiDirectorSell2,000$48.18$96,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015John M LeonardDirectorBuy1,000$47.38$47,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Timothy W TrostCFOSell28,000$50.00$1,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Martha J DemskiDirectorSell2,000$46.03$92,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Martha J DemskiDirectorSell2,000$41.58$83,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Martha J DemskiDirectorSell2,000$34.71$69,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Martha J DemskiDirectorSell2,000$40.18$80,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Martha J DemskiDirectorSell2,000$38.38$76,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Martha J DemskiDirectorSell2,000$41.08$82,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2014John M LeonardDirectorBuy4,000$29.00$116,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Timothy W TrostCFOSell5,000$27.75$138,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014James NiedelDirectorSell1,099,949$29.39$32,327,501.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Sanderling Venture Partners V,Major ShareholderSell122,950$29.28$3,599,976.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Timothy WollaegerDirectorSell100,000$24.54$2,454,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2014Ernest MarioDirectorBuy10,000$23.19$231,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Timothy W TrostCFOSell5,000$25.13$125,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2014Timothy W TrostInsiderSell5,000$22.35$111,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Timothy W TrostCFOSell5,000$22.74$113,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Ernest MarioDirectorBuy10,000$14.22$142,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014M Michelle BerreyInsiderBuy14,065$14.22$200,004.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Timothy W TrostCFOSell5,000$17.41$87,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2014Timothy W TrostInsiderSell5,000$18.67$93,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Timothy W TrostCFOSell5,000$25.37$126,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Timothy W TrostCFOSell5,000$19.29$96,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014Timothy W TrostCFOSell5,000$18.26$91,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013Timothy W TrostCFOSell5,000$15.21$76,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Ernest MarioDirectorBuy5,000$13.90$69,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Rodman L DrakeDirectorBuy1,000$14.35$14,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Ernest MarioDirectorBuy8,000$15.20$121,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Ernest MarioDirectorBuy7,500$15.25$114,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Rodman L DrakeDirectorBuy1,000$15.56$15,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Timothy W TrostCFOSell5,000$16.04$80,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell585,602$15.51$9,082,687.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013Vii L P CanaanDirectorSell674,771$15.51$10,465,698.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Ernest MarioDirectorBuy5,064$15.82$80,112.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Ernest MarioDirectorBuy5,960$17.20$102,512.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/23/2013M Michelle BerreyInsiderBuy5,540$18.70$103,598.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Ernest MarioDirectorBuy4,040$17.48$70,619.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Chimerix (NASDAQ:CMRX)
DateHeadline
06/24/16 07:03 AMChimerix, Inc. (CMRX) Current Analyst Ratings - Fiscal Standard
06/24/16 07:03 AMChimerix Inc. (CMRX) Hits New 52-week Low During June 21 Session - Equities.com
06/20/16 01:14 PMETF’s with exposure to Chimerix, Inc. : June 20, 2016 -
06/19/16 03:06 PMChimerix, Inc. (CMRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/19/16 07:50 AMChimerix Inc. (CMRX) Hits New 52-week Low During June 16 Session - Equities.com
06/16/16 07:39 AMChimerix Inc. (CMRX) Hits New 52-week Low During June 14 Session - Equities.com
06/14/16 03:11 PMTwo Stocks within Traders Limelight: Mallinckrodt plc (NYSE:MNK) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/13/16 02:44 PMTrending Stocks Update: Chimerix, Inc. (NASDAQ:CMRX), Gentex Corp. (NASDAQ:GNTX) - Beacon Chronicle
06/13/16 11:14 AMNASDAQ New Lows: Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC), Chimerix, Inc. (NASDAQ:CMRX), ImmunoGen ... - KC Register
06/09/16 03:26 PMOverview of Stock's Trend: Synthetic Biologics, Inc (NYSEMKT:SYN) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/08/16 11:49 AMTraders Targeted Movers: Centene Corporation (NYSE:CNC) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/07/16 11:34 AMInvestors Attention Alert: TherapeuticsMD, Inc. (NYSEMKT:TXMD) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/07/16 07:18 AMChimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium - [at noodls] - DURHAM, N.C., June 07, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, ...
06/07/16 07:00 AMChimerix to Participate in Panel on North Carolina’s Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium - [GlobeNewswire] - DURHAM, N.C., June 07, 2016-- Chimerix, a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and ...
06/06/16 03:06 PMTrading updates about two Stocks: Alkermes plc (NASDAQ:ALKS) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/03/16 03:25 PMHow Analysts Feel About Chimerix Inc (NASDAQ:CMRX)? - HNN
06/03/16 03:25 PMEarnings Overview of the Stocks: Chimerix, Inc. (NASDAQ:CMRX), Total System Services, Inc. (NYSE:TSS) - Beacon Chronicle
06/02/16 03:24 PMChimerix, Inc. (NASDAQ:CMRX) Stock Update & Estimates - Stock Tick Tock - Chimerix, Inc. (NASDAQ:CMRX) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Chimerix, Inc. (NASDAQ:CMRX) to post earnings of $-0.52 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/02/16 11:49 AMChimerix Incorporated (NASDAQ:CMRX) Sellers Covered 14.46% of Their Shorts - HNN - Chimerix Incorporated (NASDAQ:CMRX) Sellers Covered 14.46% of Their ShortsHNNThe short interest to Chimerix Incorporated's float is 11.47%. The stock increased 0.41% or $0.02 during the last trading session, hitting $4.92. About 709,509 shares traded hands. Chimerix Inc (NASDAQ:CMRX) has declined 86.30% since October 26, 2015 ...and more »
06/01/16 09:26 PMInsiders Are Gradually Buying Chimerix, Inc. (NASDAQ:CMRX) - HNN - Insiders Are Gradually Buying Chimerix, Inc. (NASDAQ:CMRX)HNNAccording to the latest SEC filings, insiders at Chimerix, Inc. (NASDAQ:CMRX) have increased their position in the stock by 34.85% over the past 6 months. Insiders now own 1.80% of total outstanding shares. There are both legal and illegal types of ...
06/01/16 11:52 AMBuy, Sell Or Hold Rating For Chimerix, Inc. (CMRX)? - Share Trading News - Buy, Sell Or Hold Rating For Chimerix, Inc. (CMRX)?Share Trading News02/23/2016 – Chimerix, Inc. had its “mkt perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 10 price target on the stock. 02/23/2016 – Chimerix, Inc. was downgraded to “equal-weight” by analysts at Barclays. They now ...
05/31/16 08:59 PMStock Review and Earnings Check on Chimerix, Inc. (NASDAQ:CMRX) - HNN - Stock Review and Earnings Check on Chimerix, Inc. (NASDAQ:CMRX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Chimerix, Inc. (NASDAQ:CMRX) to ...and more »
05/31/16 08:39 AMAnalysts Set 1-Year Price Target Of $8.375 On Chimerix, Inc. (NASDAQ:CMRX) Stock - Investor Newswire - Analysts Set 1-Year Price Target Of $8.375 On Chimerix, Inc. (NASDAQ:CMRX) StockInvestor NewswireSell-side analysts reveal their outlook on Chimerix, Inc. (NASDAQ:CMRX) stock. As of 2016-05-28, the stock has ABR of 2.92. This methodology prompts shareholders to invest in stock if it has a rating of 1. The ABR was known considering the price ...and more »
05/31/16 08:39 AMBroker Outlook For The Week Ahead: Chimerix, Inc. (CMRX) - Share Trading News - Broker Outlook For The Week Ahead: Chimerix, Inc. (CMRX)Share Trading NewsChimerix, Inc. (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, ...
05/30/16 12:02 AMStock Rating Review for Chimerix, Inc. (NASDAQ:CMRX) - HNN - Stock Rating Review for Chimerix, Inc. (NASDAQ:CMRX)HNNCovering equity analysts presently have a consensus stock rating of 2.92 on shares of Chimerix, Inc. (NASDAQ:CMRX). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is ...and more »
05/27/16 07:21 PMChimerix, Inc. (NASDAQ:CMRX) Impact Score At 60 - Investor Newswire - Chimerix, Inc. (NASDAQ:CMRX) Impact Score At 60Investor NewswireAlpha One explored various online articles released on Chimerix, Inc. (NASDAQ:CMRX), and it set a daily sentiment score of 0.123 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content ...and more »
05/25/16 06:53 PMInsiders Are Gradually Buying Chimerix, Inc. (NASDAQ:CMRX) - Wall Street Hints and News - Insiders Are Gradually Buying Chimerix, Inc. (NASDAQ:CMRX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Chimerix, Inc. (NASDAQ:CMRX) have increased their position in the stock by 34.88% over the past 6 months. Insiders now own 1.80% of total outstanding shares. There are both legal and illegal types of ...and more »
05/25/16 12:22 AMTarget Check and Stock Performance Recap Chimerix, Inc. (NASDAQ:CMRX) - Wall Street Hints and News - Target Check and Stock Performance Recap Chimerix, Inc. (NASDAQ:CMRX)Wall Street Hints and NewsIn recent session activity, Chimerix, Inc. (NASDAQ:CMRX) shares have traded +0.42%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been recorded $-0.70 ...and more »
05/22/16 11:31 PMStock Rating Review for Chimerix, Inc. (NASDAQ:CMRX) - Wall Street Hints and News - Stock Rating Review for Chimerix, Inc. (NASDAQ:CMRX)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 2.92 on shares of Chimerix, Inc. (NASDAQ:CMRX). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is ...and more »
05/21/16 12:04 AMAre Analysts Bullish Chimerix Inc (NASDAQ:CMRX) After Last Week? - Wall Street Hints and News - Are Analysts Bullish Chimerix Inc (NASDAQ:CMRX) After Last Week?Wall Street Hints and NewsOut of 9 analysts covering Chimerix Inc (NASDAQ:CMRX), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Chimerix Inc has been the topic of 16 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Below is a ...
05/20/16 12:11 AMInsiders Are Buying Chimerix, Inc. (NASDAQ:CMRX) - Wall Street Hints and News - Insiders Are Buying Chimerix, Inc. (NASDAQ:CMRX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Chimerix, Inc. (NASDAQ:CMRX) have increased their position in the stock by 86.28%. Insiders now own 1.00% of total outstanding shares. There are both legal and illegal types of insider trading. Illegal ...and more »
05/19/16 06:10 PMETF’s with exposure to Chimerix, Inc. : May 19, 2016 -
05/18/16 06:59 PMShare Recap and Earnings Focus on Chimerix, Inc. (NASDAQ:CMRX) - Wall Street Hints and News - Share Recap and Earnings Focus on Chimerix, Inc. (NASDAQ:CMRX)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Chimerix, Inc.and more »
05/18/16 06:59 PMTrending Stocks: Sandridge Mississippian Trust II (NYSE:SDR), Chimerix, Inc. (NASDAQ:CMRX), Albany International ... - KC Register - Trending Stocks: Sandridge Mississippian Trust II (NYSE:SDR), Chimerix, Inc. (NASDAQ:CMRX), Albany International ...KC RegisterOn 9 May, Chimerix, Inc. (NASDAQ:CMRX) reported a net loss of $26.3 million, or $0.57 per basic and diluted share, for the first quarter of 2016. During the same period in 2015, the company recorded a net loss of $22.3 million, or $0.54 per basic and ...and more »
05/18/16 06:59 PMChimerix, Inc. (CMRX) Updated Broker Price Targets - Share Trading News - Chimerix, Inc. (CMRX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Chimerix, Inc. (CMRX). The latest reports which are currently in issue on Wednesday 18th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...and more »
05/17/16 12:04 PMCHIMERIX INC Financials -
05/17/16 11:10 AMInsider Buying Summary: Chimerix Inc (NASDAQ:CMRX) - The Point Review - The Point ReviewInsider Buying Summary: Chimerix Inc (NASDAQ:CMRX)The Point ReviewChimerix Inc (NASDAQ:CMRX) insiders have most recently took part in a trading activity. On 5/13/2016 Mario Ernest, Director bought 10,000 shares having total worth of $45,328 at the price of $4.53 per share, following the transaction a total of 331,440 ...Recently Changed Price Targets On Chimerix, Inc. (CMRX)Risers & FallersChimerix Inc (CMRX) Files Form 4 Insider Buying : Ernest Mario Buys 10000 SharesMarket DigestChimerix, Inc. (NASDAQ:CMRX) Hovering Around $4.55Vanguard TribuneThe Post -Analyst Ratingsall 6 news articles »
05/16/16 12:22 PMConsensus Rating Review for Chimerix, Inc. (NASDAQ:CMRX) - Wall Street Hints and News - Consensus Rating Review for Chimerix, Inc. (NASDAQ:CMRX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 2.92 on shares of Chimerix, Inc. (NASDAQ:CMRX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/16/16 12:22 PMNext Weeks Broker Price Targets For Chimerix, Inc. (CMRX) - Share Trading News - Next Weeks Broker Price Targets For Chimerix, Inc. (CMRX)Share Trading NewsChimerix, Inc. has a 50 day moving average of 5.50 and a 200 day moving average of 16.07. The stock's market capitalization is 210.27M, it has a 52-week low of 4.36 and a 52-week high of 58.04. The share price of the company (CMRX) was down -0.44%, ...and more »
05/16/16 09:55 AMChimerix, Inc. :CMRX-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/13/16 12:44 AMOversold Conditions For Chimerix (CMRX) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Chimerix Inc. (CMRX) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $4.55 per share. By comparison ...
05/11/16 12:37 AMChimerix Inc. (CMRX) is Trading Lower on Unusual Volume for May 09 - Equities.com - Chimerix Inc. (CMRX) is Trading Lower on Unusual Volume for May 09Equities.comChimerix Inc. (CMRX) experienced unusually high volume on May. 09, as the stock lost 4.1% to a closing price of $4.91. The stock saw 6.51 million shares trade hands over the course of the day on 30,666 trades. Given that the stock's average daily ...
05/10/16 07:27 PMTrading the Biotech News: Chimerix, Inc. (NASDAQ:CMRX), Illumina Inc. (NASDAQ:ILMN) - Street Register - Trading the Biotech News: Chimerix, Inc. (NASDAQ:CMRX), Illumina Inc. (NASDAQ:ILMN)Street RegisterChimerix, Inc. (NASDAQ:CMRX) lost -4.1% by the end of recent close at $4.91. For the ongoing quarter, the 9 Wall Street analysts providing adjusted earnings per share outlook have a consensus estimate of $-$0.54/share, which would compare with $-$0.59 ...and more »
05/10/16 07:27 PMYesterday's Biggest Movers: Chimerix, Inc. (NASDAQ:CMRX) , Relypsa, Inc. (NASDAQ:RLYP) - Is stories - Yesterday's Biggest Movers: Chimerix, Inc. (NASDAQ:CMRX) , Relypsa, Inc. (NASDAQ:RLYP)Is storiesChimerix, Inc. (NASDAQ:CMRX) decreased -4.10% to $4.91 while traded 6.52 million shares on 5/9/2016. The stock price negotiated for value between $4.90 to $6.10 in recent trading session. During the past 52 weeks, the stock's price witnessed a minimum ...and more »
05/10/16 07:27 PMTwo Buzzers within Analysts Radar: Chimerix, Inc. (NASDAQ:CMRX) , Astrazeneca PLC (NYSE:AZN) - Street Updates - Two Buzzers within Analysts Radar: Chimerix, Inc. (NASDAQ:CMRX) , Astrazeneca PLC (NYSE:AZN)Street UpdatesOn 5/9/2016, Chimerix, Inc. (NASDAQ:CMRX) ended trading session lower at $4.91 with -4.10%. The company traded a volume of 6.52 million shares as comparison to average volume of 2.05 million shares. During the 52 –week period, the stock's price ...and more »
05/10/16 12:17 AMScorching Biotech Stock: Chimerix Inc (NASDAQ:CMRX) - The Point Review - NewsWay 21Scorching Biotech Stock: Chimerix Inc (NASDAQ:CMRX)The Point ReviewShare of Chimerix Inc (NASDAQ:CMRX) traded on 7.62 percent above secure line at 2:09PM EDT in order to take the company's stock at the price of $5.51. At the time of writing the stock exchanged hands 3.75 million shares versus average trading capacity ...Chimerix Inc (CMRX) Shares Up 14.6% Following Better-Than-Expected EarningsNewsWay 21Current Price Targets For Chimerix, Inc. (CMRX)Risers & FallersNotable Stocks Under Consideration: Chimerix Inc (NASDAQ:CMRX), Walt Disney Co (NYSE:DIS)NYSE Journal (press release)Vanguard Tribune -Web Breaking News -Share Trading Newsall 22 news articles »
05/09/16 07:08 PMChimerix Inc.: Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results - DURHAM, N.C., May 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported top-line results from an interim analysis of the AdVise trial of brincidofovir for ...
05/09/16 07:08 PMChimerix (CMRX) Flagged As Strong On High Volume - See the FREE profile for CMRX NOW at Trade-Ideas More details on CMRX: Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States. Currently there is 1 ...
05/09/16 07:08 PMHere’s Why Chimerix Inc is Rallying Today - Chimerix Inc. (NASDAQ:CMRX) stock climbed up over 15% today based on a bottom-line beat for the first quarter of fiscal year 2016 (1QFY16) along with positive interim data for its AdVise trial of brincidofovir for the treatment of serious adenovirus (AdV ...
05/09/16 11:22 AMEdited Transcript of CMRX earnings conference call or presentation 9-May-16 12:30pm GMT -
About Chimerix

Chimerix logoChimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company's lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CMRX
  • CUSIP:
Key Metrics:
  • Previous Close: $3.73
  • 50 Day Moving Average: $4.52
  • 200 Day Moving Average: $8.88
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $172.37M
  • Current Quarter EPS Consensus Estimate: $-2.06 EPS
Additional Links:
Chimerix (NASDAQ:CMRX) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha